A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Trial to Evaluate the Safety and Efficacy of YH22162 in Subjects With Essential Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment

NCT02620163 Phase 3 COMPLETED

To evaluate efficacy and safety of YH22162 versus telmisartan / amlodipine treatment in patients with hypertension inappropriately controlled on telmisartan/amlodipine treatment

Details

Lead sponsor	Yuhan Corporation
Phase	Phase 3
Status	COMPLETED
Enrolment	381
Start date	2015-12
Completion	2016-12

Conditions

• Hypertension

Interventions

• telmisartan/amlodipine 40/5mg
• YH22162 40/5/12.5 mg
• telmisartan/amlodipine 80/5mg
• YH22162 80/5/25 mg
• telmisartan/amlodipine 40/5mg placebo
• YH22162 40/5/12.5 mg placebo
• telmisartan/amlodipine 80/5mg placebo
• YH22162 80/5/25 mg placebo

Primary outcomes

• Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8 — baseline and week 8

Countries

South Korea